SYNACT
SynAct Pharma AB
Save
245.44M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease.
Similar securities
Based on sector and market capitalization
Report issue